community download

Download Michael Karl Bauer's presentation

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Michael Karl BauerDaratumumab, a novel therapeutic human CD38 monoclonal antibody – new treatment option in Multiple Myeloma

Michael Karl Bauer began his discussion into Daratumumab by detailing Multiple Myeloma: 

  • 10-15% of all hematological cancers
  • Most prevalent hematological malignancy in people over 65 years of age
  • 185,000 patients (prevalence) and over 47,000 new cases (incidence) estimated in US, EU-5 and Japan in 2019
  • Despite new treatments MM remains incurable - mean life expectancy ~6-7 years

"Daratumumab A Human CD38 mAb with Broad-Spectrum Killing Activity" could hold the key to treatment. Download this presentation to find out how.

Thank you for downloading the presentation. To receive your copy of the PDF, please fill in the form to your right.
 

Thanks,
European Antibody Congress Team.